Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Kim
Peter J Neumann

Showing results (1-10 of 435) with videos related to

Pageof 44
Sort By:
Annals of Internal Medicine|November 5, 2019
Comparative Modeling to Inform Health Policy Decisions: A Step ForwardDavid D Kim, Peter J Neumann
JAMA|April 18, 2023
Cost-effectiveness Thresholds Used by Study Authors, 1990-2021Peter J Neumann, David D Kim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2023
Author ReplyDavid D Kim, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 10, 2022
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional IssuesMeghan I Podolsky, Isabel Present, Peter J Neumann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 31, 2020
Measuring "Fearonomic Effects" in Valuing Therapies: An Application to COVID-19 in ChinaSiyu Ma, David D Kim, Joshua T Cohen, et al.
BMJ Global Health|June 11, 2019
Taking stock of cost-effectiveness analysis of healthcare in ChinaThomas Butt, Gordon G Liu, David D Kim, et al.
Health Affairs (Project Hope)|November 19, 2020
Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 PandemicPeter J Neumann, Joshua T Cohen, David D Kim, et al.
BMJ Global Health|March 6, 2020
Are low and middle-income countries prioritising high-value healthcare interventions?Ashley A Leech, David D Kim, Joshua T Cohen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 15, 2018
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY StudiesAshley A Leech, David D Kim, Joshua T Cohen, et al.
The American Journal of Managed Care|September 15, 2020
Crisis into opportunity: can COVID-19 help set a path to improved health care efficiency?David D Kim, Daniel A Ollendorf, Peter J Neumann, et al.
Pageof 44

Showing results (1-10 of 435) with videos related to

Sort By:
Pageof 44
Annals of Internal Medicine|November 5, 2019
Comparative Modeling to Inform Health Policy Decisions: A Step ForwardDavid D Kim, Peter J Neumann
JAMA|April 18, 2023
Cost-effectiveness Thresholds Used by Study Authors, 1990-2021Peter J Neumann, David D Kim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2023
Author ReplyDavid D Kim, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 10, 2022
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional IssuesMeghan I Podolsky, Isabel Present, Peter J Neumann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 31, 2020
Measuring "Fearonomic Effects" in Valuing Therapies: An Application to COVID-19 in ChinaSiyu Ma, David D Kim, Joshua T Cohen, et al.
BMJ Global Health|June 11, 2019
Taking stock of cost-effectiveness analysis of healthcare in ChinaThomas Butt, Gordon G Liu, David D Kim, et al.
Health Affairs (Project Hope)|November 19, 2020
Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 PandemicPeter J Neumann, Joshua T Cohen, David D Kim, et al.
BMJ Global Health|March 6, 2020
Are low and middle-income countries prioritising high-value healthcare interventions?Ashley A Leech, David D Kim, Joshua T Cohen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 15, 2018
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY StudiesAshley A Leech, David D Kim, Joshua T Cohen, et al.
The American Journal of Managed Care|September 15, 2020
Crisis into opportunity: can COVID-19 help set a path to improved health care efficiency?David D Kim, Daniel A Ollendorf, Peter J Neumann, et al.
Pageof 44